Director/PDMR Shareholding

15 January 2013

Instem plc
("Instem", the "Company" or the "Group")

Director/PDMR Shareholding

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that Chief Executive Officer, Phil Reason has been granted options over 23,429 ordinary shares of 10p each ("Ordinary Shares") and Chief Financial Officer, Nigel Goldsmith has been granted options over 15,000 Ordinary Shares. These options become exercisable after a period of three years subject to market based performance criteria, pursuant to the rules of the Company’s All Staff LTIP and approved by the Remuneration Committee on 18 December 2012. The exercise price of 90p represents the closing mid-market price of the Ordinary Shares as at 14 January 2013.

For further information, please contact:

Instem plc
Phil Reason, CEO +44 (0) 1785 825600
Nigel Goldsmith, CFO  
N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Richard Lindley  
Nick Owen  
James White  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8000
Paul Cornelius or
Sam Allen  
Helen Cresswell  
Paul Whittington  

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.

To learn more about Instem solutions and its mission, please visit